Stock AnalizElanco Animal Health Inc ELAN
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Elanco Animal Health Inc (ELAN) is a healthcare company listed in the US with a market value of about $13.4B. In the twelve months to September 30, 2026 it had revenue of $5.1B and net income of -$147M, a net margin of -2.9%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 32.8, 5-year revenue growth of 8% a year, a 5-year average ROIC of -2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 80% below the current price.
Score: 1.0 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- Positive free cash flow
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1B | $4.7B | $4.4B | $4.4B | $4.4B | $4.8B | $3.3B | $3.1B | $3.1B | $2.9B | $2.9B |
| Net income | -$147M | -$232M | $338M | -$1.2B | -$78M | -$483M | -$574M | $68M | $86M | -$311M | -$48M |
| Free cash flow | $408M | $284M | $394M | $131M | $281M | $324M | -$176M | $84M | $353M | $75M | $46M |
| EPS (diluted) | $-0.30 | $-0.47 | $0.68 | $-2.50 | $-0.16 | $-0.99 | $-1.30 | $0.18 | $0.28 | $-1.06 | $-0.16 |
| Net margin | -2.9% | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% | -17.5% | 2.2% | 2.8% | -10.8% | -1.6% |
| ROIC | — | -1.7% | 3.2% | -7.8% | -0.4% | -3.5% | -3.9% | 0.9% | 1.1% | -2.4% | -0.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $31.00, 16% above the current price; targets range from $25.00 to $35.00; the consensus rating is “Buy”; expected EPS is $1.18 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Elanco Animal Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 80% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Elanco Animal Health pay a dividend?
Not currently.
Is Elanco Animal Health a good stock to buy?
We do not give buy or sell advice. Elanco Animal Health scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.